ASO Visual Abstract: Combination of Skeletal Muscle Mass and Density Predicts Postoperative Complications and Survival of Patients with Non-small Cell Lung Cancer

2021 ◽  
Author(s):  
Changbo Sun ◽  
Masaki Anraku ◽  
Takuya Kawahara ◽  
Takahiro Karasaki ◽  
Chihiro Konoeda ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Skeletal Muscle ◽  
Postoperative Complications ◽  
Small Cell Lung Cancer ◽  
Muscle Mass ◽  
Cell Lung Cancer ◽  
Skeletal Muscle Mass ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals A comparison of CT based measures of skeletal muscle mass and density from the Th4 and L3 levels in patients with advanced non-small-cell lung cancer

2018 ◽  
Vol 73 (7) ◽  
pp. 1069-1076 ◽  
Author(s):  
Bjørn H. Grønberg ◽  
Bjørg Sjøblom ◽  
Tore Wentzel-Larsen ◽  
Vickie E. Baracos ◽  
Marianne J. Hjermstad ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Skeletal Muscle ◽  
Small Cell Lung Cancer ◽  
Muscle Mass ◽  
Cell Lung Cancer ◽  
Skeletal Muscle Mass ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals EP-1201: Impact of low skeletal muscle mass on survival after SBRT for non-small cell lung cancer

2016 ◽  
Vol 119 ◽  
pp. S570
Author(s):  
Y. Matsuo ◽  
T. Mitsuyoshi ◽  
A. Nakamura ◽  
Y. Iizuka ◽  
T. Kishi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Skeletal Muscle ◽  
Small Cell Lung Cancer ◽  
Muscle Mass ◽  
Cell Lung Cancer ◽  
Skeletal Muscle Mass ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Skeletal muscle mass predicts the outcome of nivolumab treatment for non-small cell lung cancer

Medicine ◽  
2020 ◽  
Vol 99 (7) ◽  
pp. e19059 ◽  
Author(s):  
Mariko Tsukagoshi ◽  
Takehiko Yokobori ◽  
Toshiki Yajima ◽  
Toshitaka Maeno ◽  
Kimihiro Shimizu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Skeletal Muscle ◽  
Small Cell Lung Cancer ◽  
Muscle Mass ◽  
Cell Lung Cancer ◽  
Skeletal Muscle Mass ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Staging of nutrition disorders in non‐small‐cell lung cancer patients: utility of skeletal muscle mass assessment

2019 ◽  
Vol 10 (4) ◽  
pp. 782-793 ◽  
Author(s):  
Sami Antoun ◽  
Hugues Morel ◽  
Pierre‐Jean Souquet ◽  
Veerle Surmont ◽  
David Planchard ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Skeletal Muscle ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Nutrition Disorders

scholarly journals Impact of Sarcopenia and Inflammation on Patients with Advanced Non-Small Cell Lung Cancer (NCSCL) Treated with Immune Checkpoint Inhibitors (ICIs): A Prospective Study

Cancers ◽  
2021 ◽  
Vol 13 (24) ◽  
pp. 6355
Author(s):  
Marta Tenuta ◽  
Alain Gelibter ◽  
Carla Pandozzi ◽  
Grazia Sirgiovanni ◽  
Federica Campolo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Skeletal Muscle ◽  
Small Cell Lung Cancer ◽  
Muscle Mass ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Skeletal Muscle Mass ◽  
Checkpoint Inhibitors ◽  
Small Cell ◽  
Small Cell Lung

Background: Sarcopenia is a condition characterized by loss of skeletal muscle mass associated with worse clinical outcomes in cancer patients. Data on sarcopenia in patients undergoing immune checkpoint inhibitors (ICI) therapy are still limited. The aim of this prospective observational study was to investigate the relationship between sarcopenia, ICI treatment response and immunological profile, in patients with advanced non-small cell lung cancer (NSCLC). Methods: Forty-seven stage IV NSCLC patient candidates for starting ICI, were enrolled from the Policlinico Umberto I outpatient Oncology. Patients underwent baseline blood test, inflammatory markers, cytokine assessment and body composition with dual-energy X-ray absorptiometry (DXA). Sarcopenia was defined with appendicular skeletal muscle mass over height2 (ASM/heigh2). Results: Overall, 19/47 patients (40.4%) results were sarcopenic. Sarcopenic patients showed significantly shorter PFS than non-sarcopenic ones (20.3 weeks, 95% CI 7.5–33.1 vs. 61 weeks, 95% CI 22.5–99.4, p = 0.047). Specifically, they had an 8.1 times higher risk of progression disease (PD) than non-sarcopenic patients (OR 8.1, 95%, p = 0.011). Conclusions: Sarcopenic patients showed worse PFS and had a higher risk of PD compared to non-sarcopenic ones. Therefore, sarcopenia may reflect the increased metabolic activity of more aggressive tumors, which involves systemic inflammation and muscle wasting and could be considered a negative predictive factor for ICI response.

Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors

2020 ◽  
Vol 146 (5) ◽  
pp. 1217-1225 ◽  
Author(s):  
Kazuki Takada ◽  
Yasuto Yoneshima ◽  
Kentaro Tanaka ◽  
Isamu Okamoto ◽  
Mototsugu Shimokawa ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Skeletal Muscle ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Clinical Impact ◽  
Small Cell Lung ◽  
Muscle Area ◽  
Skeletal Muscle Area

scholarly journals Prognostic Impact of Postoperative Skeletal Muscle Decrease in Non-Small Cell Lung Cancer

2020 ◽  
Vol 109 (3) ◽  
pp. 914-920 ◽  
Author(s):  
Shinkichi Takamori ◽  
Tetsuzo Tagawa ◽  
Gouji Toyokawa ◽  
Mototsugu Shimokawa ◽  
Fumihiko Kinoshita ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Skeletal Muscle ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Prognostic Impact ◽  
Small Cell Lung

scholarly journals Can radiomics help to predict skeletal muscle response to chemotherapy in stage IV non-small cell lung cancer?

2019 ◽  
Vol 120 ◽  
pp. 107-113 ◽  
Author(s):  
E.E.C. de Jong ◽  
K.J.C. Sanders ◽  
T.M. Deist ◽  
W. van Elmpt ◽  
A. Jochems ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Skeletal Muscle ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Stage Iv ◽  
Small Cell ◽  
Small Cell Lung ◽  
Muscle Response ◽  
Response To Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document